Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery
Status:
Terminated
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
In spite of the fact that the post-myocardial infarction survival rate has improved with
recent medical advances, reduced heart function attributed to irreversible loss of viable
cardiomyocytes is still a major clinical problem.
The aim of the current study is to determine whether intramyocardial injection of autologous
CD133+ bone marrow stem cells yields a functional benefit in addition to coronary artery
bypass graft (CABG) surgery in patients with chronic ischemic coronary artery disease.
Phase:
Phase 3
Details
Lead Sponsor:
Miltenyi Biotec B.V. & Co. KG Miltenyi Biotec GmbH